The racemic prodrug BAY R3401 suppresses hepatic glycogenolysis. BAY W1807, the active metabolite of BAY R3401, inhibits muscle glycogen phosphorylase a and b. We investigated whether BAY R3401 reduces hepatic glycogenolysis by allosteric inhibition or by phosphatasecatalyzed inactivation of phosphorylase. In gel-filtered liver extracts, racemic BAY U6751 (containing active BAY W1807) was tested for inhibition of phosphorylase in the glycogenolytic (in which only phosphorylase a is active) and glycogen-synthetic (for the evaluation of a:b ratios) directions. Phosphorylase inactivation by endogenous phosphatase was also studied. In liver extracts, BAY U6751 (0.9-36 µmol/l) inhibited glycogen synthesis by phosphorylase b (notwithstanding the inclusion of AMP), but not by phosphorylase a. Inhibition of phosphorylase-a-catalyzed glycogenolysis was partially relieved by AMP (500 µmol/l). BAY U6751 facilitated phosphorylase-a dephosphorylation. Isolated hepatocytes and perfused livers were tested for BAY R3401-induced changes in phosphorylase-a:b ratios and glycogenolytic output. Though ineffective in extracts, BAY R3401 (0.25 µmol/l-0.5 mmol/l) promoted phosphorylase-a dephosphorylation in hepatocytes. In perfused livers exposed to dibutyryl cAMP (100 µmol/l) for maximal activation of phosphorylase, BAY R3401 (125 µmol/l) inactivated phosphorylase by 63% but glucose output dropped by 83%. Inhibition of glycogenolysis suppressed glucose-6-phosphate (G6P) levels. Activation of glycogen synthase after phosphorylase inactivation depended on the maintenance of G6P levels by supplementing glucose (50 mmol/l). We conclude that the metabolites of BAY R3401 suppress hepatic glycogenolysis by allosteric inhibition and by the dephosphorylation of phosphorylase a.
T
here is a general interest in the development of potent and specific inhibitors of hepatic glycogen phosphorylase. Such inhibitors provide a tool to further our understanding of the physiological role of hepatic glycogen handling in the regulation of hepatic glucose output (1) . Moreover, they may be potential adjuvants in the treatment of type 2 diabetes (2) .
The hyperglycemia observed in type 2 diabetes is caused by reduced peripheral glucose deposition and by inappropriate hepatic glucose output, resulting from multiorgan insulin resistance and inadequate insulin secretion (3) . Inappropriate hepatic glucose production significantly contributes to the characteristic postabsorptive hyperglycemia in type 2 diabetic patients (4) . A reset of the balance between insulin and counterregulatory hormones results in the mobilization of peripheral muscle glycogen stores, and the resulting lactic acid fuels hepatic gluconeogenesis (5, 6) . Defects in the regulation of gluconeogenesis and of glycogen turnover and retention contribute to the loss of adequate control of hepatic glucose production (7) .
A reduction in hepatic glucose output may be achieved by the inhibition of gluconeogenesis. Agents that suppress gluconeogenesis may not be entirely safe, because they may accentuate a propensity for development of lactic acidosis (8) . They may also not be entirely efficacious, because the reduction of gluconeogenesis seems to be compensated by reduced glycogen retention, secondary to the operation of an autoregulatory mechanism (9) . Inhibitors of hepatic glycogenolysis may partially remedy this situation. As glucosyl moieties of gluconeogenic origin seem to exchange with moieties in the glycogen depot (10) , they may be retained as glycogen by inhibition of the phosphorylase leg of a futile glucose 1-phosphate (G1P) / glycogen cycle, which may become more active during starvation (11) and is not overcome by hyperinsulinemia (12) .
Hepatic glycogen synthesis and degradation are governed by glycogen synthase and phosphorylase, which are, respectively, inactivated and activated by phosphorylation (13) . Activation of glycogen synthase depends on adequate levels of glucose-6-phosphate (G6P) (14, 15) and on release of the potent allosteric inhibition of glycogen-synthase phosphatase by phosphorylase a (16, 17) . The latter explains why dephosphorylation and inactivation of phosphorylase (e.g., during glucose-induced glycogenesis) precedes dephosphorylation and activation of synthase (18) . Thus, synthase and phosphorylase are usually not simultaneously active (the former being activated only after the inactivation of the latter), and this should minimize futile G1P / glycogen cycling. A minimal amount of glycogen is needed to suppress synthase activation in the presence of active phosphorylase a (19) . Thus, in the glycogendepleted postabsorptive state, both enzymes are simultaneously active (20, 21) , which may result in increased futile glycogen cycling (11) . Inhibition and/or inactivation of phosphorylase a by pharmacological means is then expected to promote net glycogen synthesis from G6P provided by gluconeogenesis. Hepatic phosphorylase deficiency (22) and phosphorylase-kinase deficiency (23, 24) are characterized by mild postabsorptive hypoglycemia. The efficacy of hepatic phosphorylase inhibitors to lower blood glucose in obesityrelated type 2 diabetes has been demonstrated (2) .
Dimeric glycogen phosphorylase exists in 2 conformational states: a tight T-and a relaxed R-state (25) . The active R-state is induced by substrate and allosteric activators, including covalent phosphorylation, whereas the less active T-state is promoted by dephosphorylation and by a different set of allosteric inhibitors. The 3 main classes of phosphorylase inhibitors that have been tested in intact systems are as follows: 1) glucose analogs that bind near the active site (11, 26) , 2) heteroaromatic analogs of caffeine (2) that possibly bind at the purine inhibitory site, and 3) 1-alkyl-1,4-dihydropyridine-2,3-dicarboxylic acids (27) that bind at the AMP site and induce a so-called T-state, which is also adopted in the presence of the natural inhibitor G6P (28) .
It was our objective to investigate the mechanism of action of the dihydropyridine derivative, isopropyl 4-(2-chlorophenyl)-1-ethyl-2-methyl-5-oxo-1,4,5,7-tetrahydro-furo [3,4-b] pyridine-3-carboxylate (BAY R3401) as an inhibitor of glycogenolysis in rodent liver. This orally active hypoglycemic agent (1, 27) curbs hepatic glucose production and suppresses the phosphorylase activity measured in liver homogenates of the treated animals. BAY R3401 is metabolized to the 1,4-dihydropyridine-2,3-dicarboxylate, BAY W1807, a potent inhibitor of muscle phosphorylase b (28) and a (29) . The active dicarboxylate, BAY W1807 corresponds to one of the enantiomers in BAY R3401 (1) , in which the fused 5-ring lactone ring has been oxidized and opened (Fig. 1) . Only the active (-) S-enantiomer fits in the binding pocket on phosphorylase (28, 29) . The (+)-enantiomer is completely inactive. As a source of the active compound, we used the racemic mixture BAY U6751, which contains the active enantiomer BAY W1807 for 50%.
In the present study, we wanted to investigate whether the mechanism of suppression of hepatic glycogenolytic glucose production by these compounds involved inactivation through covalent changes in the phosphorylation state of glycogen phosphorylase, and/or inhibition through changes in its catalytic efficiency resulting from noncovalent interactions with the metabolic inhibitor.
RESEARCH DESIGN AND METHODS
Experimental design. To distinguish inactivation of phosphorylase by dephosphorylation from direct inhibition of the active a-form, we used, respectively, a glycogen-synthetic assay system (30), developed for assessment of the phosphorylation state of phosphorylase, and a physiologic glycogen-degradative assay (31) , in which only the phosphorylated a-form is catalytically active.
The effects of the active metabolite BAY U6751 (disodium salt) on the intrinsic activity of phosphorylase a or b in the various standard assays and on the inactivation of phosphorylase a through dephosphorylation by endogenous phosphatases were tested in tissue homogenates (liver phosphorylase) or on purified enzyme preparations (muscle phosphorylase). Liver extract of glucagon-pretreated rats was used as the source of hepatic phosphorylase a. To generate hepatic phosphorylase b, liver homogenates were preincubated, whereby the phosphorylase was dephosphorylated by endogenous phosphatases. Rabbit muscle phosphorylase a (32) was purchased from Sigma Chemical (St. Louis, MO). The glycogen phosphorylase b (33) from rabbit skeletal muscle was donated by M. Bollen (K.U. Leuven).
The effects of the prodrug BAY R3401 on the phosphorylation state of phosphorylase and on the catalytic efficiency of phosphorylase a in intact livers were evaluated on isolated hepatocytes and in perfused liver. The catalytic efficiency of phosphorylase a was evaluated from the hepatic output of glucose equivalents by liver treated with high levels of dibutyryl cyclic-AMP. We also assessed levels of G6P, a potential corollary of changes in glycogenolysis, and an effec-DIABETES, VOL. 49 tor in the reciprocal activation of glycogen synthase subsequent to the inactivation of glycogen phosphorylase. Materials. BAY R3401 and BAY U6751 (disodium salt) were provided by Bayer AG (Wuppertal, Germany). BAY U6751 was dissolved (730 µmol/l) in 20 mmol/l Tris buffer (pH 7.5). Stock solutions were stored at -20 °C for up to 3 months. BAY R3401 was dissolved (8.4 mmol/l) in water using hydroxypropyl-␥-cyclodextrin (Fluka Chemie AG, Buchs, Switzerland) (BAY R3401-to-cyclodextrin mol/l ratio 1:2.4) as a solubilizer (34) . The necessary control experiments were performed, which allowed us to exclude direct effects of cyclodextrin on phosphorylase activities in isolated hepatocytes, or effects of carryover of cyclodextrin in the ensuing enzymatic incubations.
Other reagents of analytical grade from various suppliers were used for the preparation of perfusion buffers and incubation media. Phosphoglucomutase and G6P dehydrogenase were purchased from Boehringer-Mannheim (Mannheim, Germany). Preparation of animals. Male Wistar-derived pfd (Louvain) rats (~250-300 g, 8-10 weeks) were fed ad libitum. Animals were cared for observing standard procedures (National Institutes of Health guideline, NIH 80-23). Glycogen-loaded livers were removed in the morning, after anesthetization of the donor animal by intraperitoneal injection with sodium pentobarbital (6 mg/100 g body wt). Where indicated, 10 min before the removal of the liver, rats were injected intraperitoneally with 70 µg glucagon, to fully activate liver phosphorylase.
Livers were either immediately homogenized for preparation of fresh liver extracts or were used in perfusion experiments or for the isolation of hepatocytes. Liver perfusion and preparation of hepatocytes. Livers were perfused (5 ml · g -1 · min -1 ) with Krebs-Henseleit buffer (pH 7.45) and gassed with O 2 /CO 2 (95/5) at 37 °C, as previously described (35) .
Hepatocytes were isolated by the collagenase method in Krebs-Henseleit-derived medium as described previously (36), but the pH was lowered to 7.2 for more reproducible control of seemingly Ca 2+ -induced cell damage (37) and variable phosphorylase activation. Viability, as tested by trypan-blue exclusion, was > 90%. Cells were used after a recovery period of 5-10 min from the final wash cycle. They were incubated (5 ϫ 10 6 cells/ml) at 37 °C in KrebsHenseleit medium supplemented with 13.5 mmol/l lactate, 1.5 mmol/l pyruvate, 0.2 mmol/l glycerol, and 2-50 mmol/l glucose. Cell suspensions (2-5 ml) were continuously shaken and gassed with O 2 /CO 2 (95:5). In situ inactivation and inhibition of phosphorylase a in perfused livers. Livers were exposed to 100 µmol/l dibutyryl cAMP to fully activate phosphorylase. BAY R3401 was tested as an inhibitor of phosphorylase-a-catalyzed glycogenolysis in recirculating mode. The rate of glycogenolysis was assessed from porto-caval metabolite gradients and from time-dependent accumulation of metabolites in the recirculating perfusate, and was correlated with the phosphorylation state of phosphorylase, assessed in liver lobes sampled at scheduled intervals.
Tissue homogenates (usually 1:6 tissue:extract; 17%, wt/vol) were prepared in an electromotor-driven Potter-Elvehjem apparatus. Tissue preparation for assay of the prevailing phosphorylation state of glycogen phosphorylase and synthase. The prevailing phosphorylation state of glycogen phosphorylase and synthase was preserved by preparing homogenates in 100 mmol/l NaF, 20 mmol/l EDTA, 5 mg/ml oyster glycogen, and 10 mmol/l glycylglycine, pH 7.4 (final concentrations) (38) . Cell suspensions were snap-frozen (in liquid N 2 ) in the above medium. Cells were broken by freeze-thawing. Cytosolic (postmicrosomal) supernatant was prepared by ultracentrifugation at 100,000g av for 45 min. Study of dephosphorylation of phosphorylase a in homogenates. The homogenate (1:4 liver:extract, wt/vol) was prepared in ice-cold 250 mmol/l sucrose, 1 mmol/l dithioerythritol, and 50 mmol/l glycylglycine, pH 7.4, centrifuged for 10 min at 8,000g av , and the supernatant (liver extract) gel-filtered on a Sephadex PD10 column (G-25 M; Pharmacia Biotech AB, Uppsala, Sweden) to remove endogenous effectors (such as AMP, glucose, G6P, etc.) of the phosphatase reaction. The stimulatory effect of glucose and dihydropyridines was tested in homogenization buffer containing 10 mmol/l (NH 4 ) 2 SO 4 to provide a minimal ionic strength (16) . Enzymatic assays. All enzymatic assays were performed at 37°C except the glycogen synthase assay, which was performed at 25°C. Assay of glycogen phosphorylase phosphorylation state. Phosphorylase was assayed in the synthetic direction in a lyotropic buffer with 5% dimethoxymethane and 2 mmol/l AMP for assay of total enzyme or with 0.5 mmol/l caffeine for selective assay of the a-form (30) . Selective assay of glycogen phosphorylase a. Phosphorylase a was assayed in the physiologic glycogenolytic direction by a spectrophotometric method (31) . The minimal physiological medium (39) contained 5 mmol/l K 3 PO 4 , 10 mg/ml glycogen and 1 mmol/l AMP in 150 mmol/l KCl, 10 mmol/l HEPES, pH 7.4 buffer. Deviations from these conditions (kinetic experiments) are given where they apply. NaF (100 mmol/l), routinely present in the synthetic phosphorylase assay, was replaced by 150 mmol/l KCl, because the former salt substantially enhances catalysis by the b-form of the enzyme. In the presence of 150 mmol/l KCl, the affinity of the enzyme for P i is markedly reduced and possibly susceptibility to inhibition is increased. Dephosphorylation of phosphorylase a by endogenous phosphatases was negligible within the short measuring time (3 min).
Glycogen synthase (active a-form and total a + b activity) was determined as previously described (40) .
Glucokinase activity was assayed with the G6P-dehydrogenase-coupled assay (41,42) on a postmicrosomal supernatant, prepared from liver homogenized (1:3 liver:homogenate) in 250 mmol/l sucrose, 1 mmol/l dithioerythritol, 1 mmol/l EDTA, 5 mmol/l HEPES, pH 7.5. The assay was performed in 100 mmol/l KCl, 7.5 mmol/l MgCl 2 , 2.5 mmol/l dithioerythritol, 50 mmol/l HEPES, pH 7.1, 0.5 or 50 mmol/l glucose, 2.5 mmol/l ATP, 0.5 mmol/l NADP, 1,750 U/l G6P-dehydrogenase, and tissue extract (1:60, wt/vol). Activities were corrected for changes in absorbancy observed in the absence of added ATP.
Glucose-6-phosphatase was measured in untreated and detergent (Chapso) -disrupted microsomes (43) with 10 mmol/l G6P. Assay of metabolites in the perfusate. Glucose (44), lactate (45) , and pyruvate (46) were determined in the perfusate by standard spectrophotometric procedures. The summed rate of net appearance of these metabolites (expressed in glucose equivalents) is taken as a measure of glycogenolytic activity. Assay of intracellular metabolites. Cells were separated from the incubation medium (47) by microcentrifugation (7,570g av for 5 s). Tissue homogenate or cell pellets were deproteinized in ice cold HClO 4 . In the neutralized extract, G6P was measured spectrophotometrically using G6P dehydrogenase (48) . Statistics. The results are shown as averages with standard error from the mean and number of observations. Curve-fitting procedures are discussed where they apply.
Inhibitor concentrations are expressed on a substance basis (micromoles per liter), without correction for the 50% purity of BAY U6751, with respect to the active enantiomer BAY W1807.
RESULTS

Studies in broken-cell systems
Evaluation of the glycogen-synthetic assay of the phosphorylation state of phosphorylase in the presence of BAY U6751. The glycogen-synthetic phosphorylase assay, in which the release of inorganic phosphate is measured, is commonly used for assay of phosphorylase activity. The test has been optimized for the quantitative determination of the phosphorylation state of phosphorylase (30) . We wanted to study the effects of the inhibitor BAY U6751 on the comparative assay of phosphorylase a and b.
As sources of predominantly liver phosphorylase a and b, we used, respectively, NaF-arrested gel-filtered liver extracts of glucagon-pretreated rats and gel-filtered extracts to which NaF was added after prior incubation to convert the enzyme into the b-form. When assayed in the synthetic direction (under the conditions used for assay of phosphorylase a/[a + b] ratios), phosphorylase a was not inhibited by up to 36 µmol/l BAY U6751 (Fig. 2) . In contrast, 36 µmol/l compound inhibited phosphorylase b almost completely.
The selective inhibition of phosphorylase b activity (Fig. 2 ) may result in an overestimation of phosphorylase a/(a + b) ratios when assayed in the presence of the inhibitor. To correct for this bias, we have systematically expressed our data on phosphorylase activation-state by reference to total enzyme activities measured in control samples in the absence of inhibitor. Kinetic study of the inhibition of hepatic (and muscle) phosphorylase a by BAY U6751. For the evaluation of BAY U6751 as an inhibitor of liver phosphorylase a under physiologic conditions, we performed a more detailed analysis (Fig. 3) of the kinetic behavior of phosphorylase a, from liver and muscle, assayed in the physiologic degradative direction under physiologic conditions in which only phosphorylase a is active (39) . In liver, the a-form is solely responsible for glycogenolysis (30) . Both the muscle and liver enzymes are sensitive to BAY U6751 and, at least for the muscle enzyme, inhibition is overcome by addition of AMP.
Although BAY U6751 proved to be an effective inhibitor, BAY R3401 was without effect on any of the enzyme activities examined in homogenates.
Inactivation of phosphorylase in gel-filtered extracts.
Protein phosphatase action, unopposed by kinases, was studied in ATP-free gel-filtered extracts. We compared rates of phosphatase-catalyzed inactivation of phosphorylase in the presence of BAY U6751, or of 10 mmol/l glucose (Fig. 4) . The prodrug BAY R3401 (tested at up to 125 µmol/l) remained without effect (not shown). Initial phosphorylase activities (mostly phosphorylase a) were hardly affected, even by the highest concentration of BAY U6751. This confirms the insensitivity of phosphorylase a to the inhibitor in this assay system (Fig. 2 ). BAY U6751 (tested at 0.9-36 µmol/l) promoted the dephosphorylation of phosphorylase in a concentrationdependent way. This is obvious from the BAY U6751-dependent drop in phosphorylase a activities (Fig. 4) . Studies in isolated hepatocytes and perfused liver BAY R3401 causes inactivation and inhibition of phosphorylase in isolated hepatocytes. The in situ sensitivity of liver phosphorylase to the prodrug BAY R3401 was tested. We determined phosphorylase a levels (as a fraction of the total (a + b) activity, prior to addition of inhibitor) in hepatocytes exposed to a range of BAY R3401 levels (Fig. 5) . In the absence of inhibitor, initial phosphorylase a levels amounted to 71 ± 6% (n = 3) of total enzyme activity. BAY R3401 facilitated the conversion of phosphorylase a into b (Fig. 5A) able manner on the concentration of inhibitor added (Fig. 5B ). Inactivation and inhibition of phosphorylase a was also confirmed when phosphorylase activity was assayed in the physiologic degradative direction, under conditions in which phosphorylase b is essentially inactive (Fig. 5C ). The more pronounced loss of activity, using the latter assay, reflects the combined effects of inactivation of the enzyme and of inhibition (Fig. 3 ) of residual phosphorylase a.
Sequential inactivation of phosphorylase and activation of synthase in isolated hepatocytes. We studied the effects of BAY R3401 on the activation state of phosphorylase and synthase in greater detail in isolated hepatocytes. We compared the effectiveness of saturating levels of BAY R3401 (250 µmol/l) with those of glucose (50 mmol/l). As expected (11, 18) , glucose hastened inactivation of phosphorylase, and promoted activation of synthase, after the typical lag phase needed for inactivation of phosphorylase below a critical threshold (< 30% in the present experiments) (Fig. 6A and B) . BAY R3401 (250 µmol/l) effectively hastened phosphorylase inactivation (Fig. 6C) . Synthase activation was attenuated despite the deep inactivation of phosphorylase (below the threshold for synthase activation established in the glucose control experiments). We have already mentioned the potential role of G6P in promoting synthase activation. In the presence of BAY R3401, G6P levels dropped significantly, presumably reflecting inhibition of glycogenolysis. When glycogenolysis is inhibited, the loss of G6P can be partly overcome by the inclusion of high levels of glucose (50 mmol/l) (Fig. 6D) . The moderate activation of synthase (Fig. 6C) was clearly enhanced by the inclusion of glucose into the medium (Fig. 6D) . BAY R3401 causes inactivation and inhibition of phosphorylase a in perfused rat liver. In an attempt to evaluate whether BAY R3401 would directly inhibit the catalytic efficiency of phosphorylase a in situ, we devised the following experiment (Fig. 7) : In perfused livers, in which phosphorylase was fully activated by prior and continued exposure to 100 µmol/l dibutyryl cAMP, we compared BAY-3401-induced changes in glycogen phosphorylase a levels with changes in hepatic glucose output. A maximal glycogenolytic response, corresponding to nearly full activation of phosphorylase, was reached within 15 min after the introduction of 100 µmol/l dibutyryl cAMP. When 125 µmol/l BAY R3401 was added, the rate of glycogenolysis dropped precipitously and then slowly declined further during the next 30 min. In the intact liver, glycogenolysis is exclusively catalyzed by phosphorylase a (30, 49) . The drop in glycogenolytic output (to 17 ± 1% of preinhibitor rates, n = 5) could be explained in part by a drop in phosphorylase a levels (to 37 ± 4% of preinhibitor levels) (Fig. 7) . Despite high levels of BAY R3401, phosphorylase inactivation, presumably opposed by cAMPdependent kinases, was less pronounced than in Fig. 5 . Excess nonproportional reduction in glycogenolytic output may be due to direct inhibition of residual phosphorylase a.
G6P dropped in parallel to the declining glycogenolysis (Fig. 7) . Phosphorylation of the glucose that accumulates in the medium (to 15.5 ± 1.4 mmol/l [n = 5] at 60 min) apparently did not suffice to counteract the diminished phosphorolytic generation of G6P. We also evaluated the activation status of glycogen synthase. Not unexpectedly, in view of the presence of dibutyryl cAMP (50), synthase a levels were low and changed little throughout the various phases of the experiment (Fig. 7A) . BAY U6751 has no effect on glucose phosphorylation or G6P dephosphorylation. The G6P lowering effect of BAY R3401 led us to evaluate possible interactions of BAY R3401 and of BAY U6751 with the glucose/G6P cycle. BAY U6751 (tested at up to 36 µmol/l) had no effect on glucokinase activity (assayed in liver homogenates [41, 42] ) or on glucose-6-phosphatase (tested in intact and detergent-disrupted rat liver microsomes [43] ) (results not shown). As part of the validation of our degradative phosphorylase assay, we also excluded the inhibition of G6P-dehydrogenase (from yeast). BAY R3401 apparently does not inhibit hepatic gluconeogenesis (1) . Thus, the G6P lowering effect of BAY R3401 (Figs. 6 and 7) , in all likelihood, is exclusively linked to the strong inhibition of glycogenolysis.
DISCUSSION
The blood-glucose lowering prodrug BAY R3401 markedly reduces basal and glucagon-stimulated hepatic glycogenolysis (1). The fact that in liver extracts of rats treated with BAY R3401 both phosphorylase a and a + b activities are reduced had been tentatively interpreted as a consequence of phosphorylase inhibition (1). Our results show that the latter effect is only a lesser part of the complex actions of BAY R3401. The prodrug BAY R3401, which was ineffective in liver homogenates, effectively reduced phosphorylase activities in hepatocytes and perfused liver. This is due to the accumulation and retention of an active inhibitor. We postulate that when effective concentrations of this inhibitor are reached, interaction with phosphorylase a makes the enzyme a better substrate for inactivation by phosphorylase-a phosphatase. This effect is reminiscent of that of glucose analogs (11, 51) and methylxanthines (52) , which bind to phosphorylase a and inhibit the enzyme while simultaneously facilitating the inactivation of the enzyme by phosphorylase-a phosphatase.
Thus, BAY R3401 (or rather, an active metabolite) promotes the conversion of phosphorylase from the a-to the b-form, and is responsible for the decline in phosphorylase a activity (Fig. 5 ) and in apparent total enzyme activity (results not shown). The exquisite sensitivity (Fig. 2) of the b-form to the presence of BAY R3401-derived inhibitor in the glycogensynthetic enzyme assay necessitates reference to total enzyme levels assayed before the addition of the inhibitor for the assessment of a:(a + b) ratios. Catalysis by phosphorylase b in this system depends on the presence of lyotropic salt, organic solvent, and AMP. BAY W1807, the active (-) S-enantiomer in BAY U6751, is known to be a potent inhibitor of muscle phosphorylase b (assayed in the synthetic direction) and to act as a competitive inhibitor with respect to the stimulation of the enzyme by AMP (28) . We confirmed this conclusion (results not shown). Liver phosphorylase b remained significantly suppressed, despite the presence of 2 mmol/l AMP. We did not further characterize the effect of BAY U6751 on the AMP dependence of liver phosphorylase b. Resistance to the inhibition of the a-form may reflect its minimal AMP dependence, and the competitive inhibition with the substrate G1P (29) may have been obscured by the deliberately high levels of G1P in this glycogen-synthetic assay system.
Although in the glycogen-synthetic assay no inhibition of phosphorylase a could be observed (Fig. 2) , the inhibitor interacts with the a-form under physiological conditions. Thus, the inhibitor facilitates the inactivation of phosphorylase a in intact liver (Fig. 7) and hepatocytes (Fig. 5) , as well as in gel-filtered homogenates (Fig. 4) . Furthermore, there is direct evidence for inhibition of phosphorylase a in the physiologic glycogenolytic direction both in an appropriate assay system (Fig. 3 ) and in perfused liver (Fig. 7) . Indeed, direct inhibition of residual phosphorylase a is responsible for the excessive reduction in glycogenolytic output (from perfused livers) (Fig. 7) beyond what can be expected from the extent of phosphorylase inactivation.
Part of our evaluation involved the nature of this allosteric interaction (Fig. 3) . In comparison with the muscle enzyme, in the liver enzyme allosteric communication between the AMP-effector site and the catalytic site is less well coupled (25) . Thus, the liver enzyme has a lower affinity for AMP, and not unexpectedly, AMP less effectively reversed inhibition of the liver enzyme (Fig. 3) . The binding of the inhibitor to muscle phosphorylase b induces a T-state, reminiscent of the binding of G6P (28) . We could not test for cooperative inhibition of phosphorylase a by G6P and BAY U6751 because detection of phosphorylase activity in our current assay relies on the coupled oxidation of G6P.
In conclusion, BAY R3401 reduces glycogenolysis, both by inactivation and by inhibition of residual phosphorylase a, which is solely responsible for glycogenolysis in the liver (30) . To what extent BAY R3401 will then also promote glycogen deposition depends on several factors: 1) suppression by the inhibitor of futile glycogen cycling driven by phosphorylase a and 2) activation of glycogen synthase. Activation of glycogen synthase b by dephosphorylation depends on the release of allosteric inhibition of synthase phosphatase by elevated levels of phosphorylase a (in the presence of glycogen) (19) . Whether the BAY R3401-induced inactivation of phosphorylase then suffices to activate synthase depends on the presence of a sufficient level of the allosteric effector G6P (11, 14, 15) . Apparently, in our glycogen-loaded incubated cells (Fig. 6 ) and perfused livers (Fig. 7) , both glycogenolysis itself and ambient glucose levels appear to be major determinants of G6P levels.
The dihydropyridine-2,3-dicarboxylic acid BAY U6751 is a potent inhibitor of hepatic glycogen breakdown and can be used as potential research tools (1) . By inhibiting hepatic glycogen breakdown, BAY R3401 may facilitate the retention of gluconeogenic glucose equivalents as glycogen. Thus, dihydropyridines of the type BAY R3401 or BAY U6751 may be developed as an adjuvant in the control of (postabsorptive) hyperglycemia in type 2 diabetes.
N. BERGANS AND ASSOCIATES
FIG. 7. BAY R3401
inactivates and inhibits phosphorylase a in perfused liver. Livers (n = 5) were perfused as described in RESEARCH DESIGN AND METHODS, with dibutyryl cAMP (100 µmol/l) and BAY R3401 (125 µmol/l, cyclodextrin-solubilized) for the time span indicated by the horizontal bars. Livers were perfused in recirculating mode. The time course of glycogenolytic output (ᮀ) was assessed from porto-caval metabolite differences. On selected liver lobes, we assayed phophorylase a () and synthase a (᭡) both as a fraction of initial total enzyme activity and G6P levels (᭺). We show averages ± SE (n = 5).
